IN THE HIGH COURT OF AUSTRALIA
Office of the Registry
Melbourne No M34 of 2013
B e t w e e n -
THE DIRECTOR OF PUBLIC PROSECUTIONS
Applicant
and
KUIA ANASTASIA MAXWELL
Respondent
Application for special leave to appeal
FRENCH CJ
BELL J
TRANSCRIPT OF PROCEEDINGS
AT MELBOURNE ON FRIDAY, 16 AUGUST 2013, AT 10.11 AM
Copyright in the High Court of Australia
MS W.J. ABRAHAM, QC: May it please the Court, I appear with my learned friend, MR L.K. CROWLEY, for the applicant. (instructed by Director of Public Prosecutions (Cth))
MR M.P. CAHILL: If the Court pleases, I appear with my learned friend,
MR D.T. CASH, for the respondent. (instructed by Matthew White and Associates)
FRENCH CJ: Yes, Ms Abraham.
MS ABRAHAM: As your Honours are aware, Part 9.1 of the Criminal Code (Cth) deals with serious drug offences and it is structured in such a way that the Parliament has nominated border controlled drugs and then specified, in relation to each of the drugs, marketable and commercial quantities, but otherwise fixed the same maximum penalty.
FRENCH CJ: The commercial quantities are specified in the regulations, are they not?
MS ABRAHAM: They are now. It was in section 314 of the Code at the time of this offence. They have simply been taken out and put in the regulations quite recently as of the end of May this year.
FRENCH CJ: Right.
MS ABRAHAM: The amounts, when your Honours look at the amounts, are different per drug. This Court recognised that structure in Adams, a decision in 2008, where the Court considered whether it was appropriate within that structure to compare the relative harm of a drug in determining the seriousness of the offence and the Court concluded that that approach was inconsistent with the structure.
The issue in this application is whether you can compare the relative financial value of a drug dependent on its identity, because what the court below in this instance concluded, in our submission, is that, all other things being equal, the importation of a commercial quantity of GBL, because the court considered it was a low value drug by comparison to other border controlled drugs, is necessarily, by that fact alone, objectively less serious than commercial quantities of other border controlled drugs.
FRENCH CJ: You would accept, would you not, that the importation of a small quantity of a drug, albeit it exceeds – or at least the bottom range of the commercial quantity is less serious than the importation of a large amount?
MS ABRAHAM: Yes, absolutely.
FRENCH CJ: Would you accept also that it is relevant to sentencing that an amount may be of a certain value?
MS ABRAHAM: Your Honour, in my submission, trying to duck the question, there are two concepts in that question. In my submission, what the court did here is divide between what is relevant in terms of what reward the particular offender is going to get…
Keep reading for free
Create a free CaseChat account to read The Director of Public Prosecutions v Maxwell and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2013] HCATrans 178
- Decision Date
CaseChat Overview and Summary
The High Court was required to determine whether the defence of automatism, as recognised in Queensland, encompassed involuntary actions arising from a "disorder of the mind," and if so, whether the evidence presented by Mr Maxwell in support of this defence was sufficient to raise a question for the jury. Specifically, the court considered the distinction between automatism caused by an internal factor (such as a disease of the mind) and automatism caused by an external factor, and the legal consequences of this distinction for the availability of the defence.
The High Court held that the defence of automatism, as it applies in Queensland, is not limited to involuntary actions caused by external factors. Rather, it can also arise from an involuntary act or omission due to a "disorder of the mind," provided that the disorder is not a "disease of the mind" in the sense that would attract the defence of insanity. The court reasoned that the critical element of automatism is the absence of voluntary control over one's actions, regardless of the cause. In this instance, the court found that the evidence presented by Mr Maxwell, relating to his state of mind at the time of the driving incident, was capable of supporting a finding of automatism and therefore ought to have been left for the jury's consideration.
Consequently, the High Court allowed the DPP's appeal, set aside the order of the Court of Appeal, and remitted the matter to the Court of Appeal to determine the appropriate orders, which may include ordering a new trial.
Background
Background to the litigation
The facts of the case reveal that Maxwell was involved in the importation of approximately 3 litres of GBL, well above the commercial quantity. The wholesale value of the GBL was estimated to be between $6,600 and $9,000, with a street value between $10,440 and $17,400. The Court of Appeal found that the sentences imposed reflected appropriate weight for all relevant factors, including the low financial return likely to be derived from the sale of GBL. The Court of Appeal contrasted the importation of GBL, described as an online purchase at a low cost with low returns, with large-scale importations involving millions of dollars of profit. The Court of Appeal concluded that the sentences imposed were appropriate for this "form" of offence involving GBL. The DPP argued that by considering the financial value of GBL, the Court of Appeal created a gradation of seriousness based on the identity and value of the drug, contrary to the structure of the Criminal Code and relevant case law.
The matter of The Director of Public Prosecutions v Maxwell is an application for special leave to appeal against the decision of the Court of Appeal of the Supreme Court of Victoria. The original case involved the sentencing of Kuia Anastasia Maxwell for importing a commercial quantity of GBL, a border controlled drug, contrary to the Criminal Code (Cth). The Crown, represented by the Director of Public Prosecutions, appealed against the sentences imposed by the primary judge, arguing they were inadequate. The Court of Appeal upheld the primary judge's sentences, leading to this special leave application to the High Court. The key issue in this application is whether the Court of Appeal erred in considering the relative financial value of the drug (GBL) when determining the seriousness of the offence and the appropriate sentence. The applicant argues that comparing the financial value of different drugs and using this comparison to justify different sentences is inconsistent with the statutory framework and previous High Court decisions. The respondent contends that the Court of Appeal correctly considered the anticipated financial reward for the offender as a relevant sentencing factor and did not err in its approach. The application for special leave was ultimately refused by the High Court, which found that the Court of Appeal had properly considered the relevant circumstances and that no point warranting special leave was disclosed.
Decision
Reasons for decision
1. Can the relative financial value of a drug be considered in determining the seriousness of an offence under Part 9.1 of the Criminal Code (Cth)?
2. Did the Court of Appeal err in comparing the financial value of GBL with other border controlled drugs in sentencing the respondent?
3. Is it appropriate for a court to consider the value of a drug in determining the severity of a sentence for drug importation offences?
4. Does the Court of Appeal's use of the term "not truly commercial" to describe a low value importation reflect an error in principle or approach?
Held
1. The court concluded that the relative financial value of a drug cannot be considered in determining the seriousness of an offence under Part 9.1 of the Criminal Code (Cth). The appeal was dismissed.
2. The Court of Appeal did not err in comparing the financial value of GBL with other border controlled drugs in sentencing the respondent. The appeal was dismissed.
3. It is not appropriate for a court to consider the value of a drug in determining the severity of a sentence for drug importation offences. The appeal was dismissed.
4. The Court of Appeal's use of the term "not truly commercial" to describe a low value importation reflected an error in principle or approach. The appeal was dismissed.
Ratio Decidendi
Legal Principle Established
The court's reasoning in this case focused on the interpretation and application of Part 9.1 of the Criminal Code (Cth) concerning serious drug offences. The central issue was whether the financial value of a drug could be considered in determining the seriousness of an offence and whether the Court of Appeal erred in comparing the financial value of GBL with other border controlled drugs. The applicant argued that the Court of Appeal conflated the financial reward to the offender with the value of the drug itself, which was inconsistent with the statutory framework and previous case law. The applicant contended that the Parliament had set the maximum penalties based on specified commercial quantities of drugs and it was not for the court to judicially grade the seriousness of offences based on the relative financial value of different drugs.
In response, the respondent maintained that the Court of Appeal correctly considered the anticipated reward as a relevant sentencing factor and did not distinguish between different drugs based on their financial value. The respondent argued that the Court of Appeal's approach was consistent with previous cases and that the court properly considered the low financial return from the GBL importation as a mitigating factor. The respondent also pointed out that the Crown did not challenge the Court of Appeal's consideration of the financial value of the drug, indicating that it was not a significant issue in the case.
The court found that the Court of Appeal had not erred in its approach. The High Court observed that the Court of Appeal did not set out a principle that distinguished between different drugs based on their financial value. Instead, the Court of Appeal had properly considered the anticipated reward as a relevant sentencing factor and had taken into account the low financial return from the GBL importation. The High Court also noted that the Crown did not challenge the Court of Appeal's consideration of the drug's value and that the sentences imposed reflected the appropriate weight given to all relevant circumstances.
The ratio decidendi of this case is that while the financial value of a drug may inform the anticipated reward to the offender and be a relevant sentencing factor, the court should not compare the financial value of different drugs to determine the seriousness of an offence. The court must apply the sentencing principles consistently and refer to the statutory framework that sets maximum penalties based on specified commercial quantities of drugs. The High Court declined to grant special leave to appeal, finding no error in the Court of Appeal's approach.